(VIANEWS) – Shares of ULTIMOVACS (Oslo Børs All-share Index_GI: ULTI.OL) rose by a staggering 21.16% in 10 sessions from $110.6 to $134.00 at 13:44 EST on Tuesday, after three consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.84% to $1,377.27, after successive sessions in a row of losses.
About ULTIMOVACS
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of $-3.98.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was 2.18%, 0.84%, and 2.72%.
ULTIMOVACS’s highest amplitude of average volatility was 2.18% (last week), 2.05% (last month), and 2.72% (last quarter).
More news about ULTIMOVACS (ULTI.OL).
